Lepu Pharmaceuticals Co., Ltd.

Primary Objective: To investigate the absorption rate and extent of betahistine hydrochloride tablets (8 mg) manufactured by Lepu Hengjiuyuan Pharmaceutical Co., Ltd., in healthy subjects under fasting or postprandial conditions, using Mylan Laboratories SAS (trade name: Serc®; strength: 8 mg) as the reference formulation, and to evaluate the bioequivalence between the test formulation and the reference formulation. Secondary Objective: To observe the safety of oral administration of the test formulation and the reference formulation in healthy subjects.

Primary objectives: To evaluate the efficacy of LPS-001 injection in the treatment of type 2 diabetes. Secondary objectives: (1) To evaluate the safety of LPS-001 injection in the treatment of type 2 diabetes. (2) To evaluate the pharmacokinetic characteristics and immunogenicity of LPS-001 injection in patients with type 2 diabetes.

Primary objective: To compare the similarity of the pharmacokinetic characteristics of LPS-001 injection and Novota® after a single dose in healthy Chinese subjects, using LPS-001 injection developed by Lepu Pharmaceutical Co., Ltd. as the test drug and semaglutide injection (Novota®) produced by Novo Nordisk A/S as the reference drug. Secondary objective: To compare the safety of LPS-001 injection and Novota® in healthy Chinese adult subjects.